BioLineRX (BLRX)

• Market cap: $10.7M
• 1 day: 4.73%
• 5 days: 15.20%
• 1 month: -10.56%
• 3 months: -29.06%
• 6 months: -84.42%
• Year to date: -71.82%
• 1 year: -88.42%
• 5 years: -95.86%
• 10 years: -99.78%
• Sector: Healthcare
• Industry: Biotechnology

About: BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

Employees: 28

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

1,500% more call options, than puts

Call options by funds: $16K | Put options by funds: $1K

0% more repeat investments, than reductions

Existing positions increased: 6 | Existing positions reduced: 6

0.06% less ownership

Funds ownership: 0.21% [Q3] → 0.15% (-0.06%) [Q4]

9% less first-time investments, than exits

New positions opened: 10 | Existing positions closed: 11

3% less funds holding

Funds holding: 32 [Q3] → 31 (-1) [Q4]

68% less capital invested

Capital invested by funds: $1.34M [Q3] → $436K (-$908K) [Q4]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $26 803% upside
• Avg. target: $26 803% upside
• High target: $26 803% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Joseph Pantginis 15% 1-year accuracy 62 / 415 met price target

803% upside $26

Buy Maintained

31 Mar 2025